Core Insights - U.S. stocks exhibited mixed performance, with the Dow Jones index increasing by approximately 200 points on Thursday [1] Company Performance - Cardinal Health, Inc. reported quarterly earnings of $2.55 per share, surpassing the analyst consensus estimate of $2.18 per share, and quarterly sales of $64.009 billion, exceeding the consensus estimate of $59.197 billion [2] - Following the positive earnings report, Cardinal Health shares surged by 17.5% to $193.26 on Thursday [2] - Guardant Health, Inc. saw its shares jump by 29.3% to $93.45 after reporting better-than-expected third-quarter results and raising its FY25 sales guidance [4] - Emergent BioSolutions Inc. experienced a 29% increase in shares to $12.11 after also reporting better-than-expected quarterly results and raising its FY25 sales guidance [4] - Glaukos Corporation's shares surged by 28.7% to $99.20 following a strong quarterly performance and an upward revision of its FY25 sales guidance [4] - C.H. Robinson Worldwide, Inc. shares rose by 21.3% to $156.66 after reporting better-than-expected third-quarter adjusted EPS results [4] - Viavi Solutions Inc. gained 21.1% to $16.93 after exceeding first-quarter estimates and issuing optimistic second-quarter guidance [4] - Perimeter Solutions, Inc. rose by 21% to $25.96 following positive earnings results [4] - FormFactor, Inc. gained 21% to $57.71 after reporting better-than-expected third-quarter results and providing favorable fourth-quarter guidance [4] - Metsera, Inc. saw a 20.9% increase to $63.15 after Novo Nordisk confirmed an unsolicited acquisition proposal [4] - Immunovant, Inc. shares increased by 20% to $26.00 [4] - Bausch Health Companies Inc. rose by 15% to $6.79 after reporting better-than-expected third-quarter results and raising its FY25 sales guidance [4] - Insmed Incorporated gained 11.8% to $186.35 after raising its FY2025 global ARIKAYCE sales guidance [4] - XPO, Inc. shares rose by 11.3% to $138.82 following strong quarterly earnings [4] - WESCO International, Inc. increased by 10% to $251.41 after posting positive quarterly results [4] - Calix, Inc. gained 9.3% to $68.00 after reporting better-than-expected third-quarter results and issuing optimistic current-quarter guidance [4] - CommScope Holding Company, Inc. shares rose by 8.1% to $17.02 after exceeding quarterly estimates [4] - Huntington Ingalls Industries, Inc. gained 7.3% to $320.12 after reporting third-quarter results above estimates [4] - Extreme Networks, Inc. jumped by 7.2% to $19.31 following positive quarterly earnings [4] - Fox Corporation gained 6.4% to $57.83 after reporting better-than-expected quarterly results and announcing a $1.5 billion accelerated share buyback [4] - Alphabet Inc. rose by 5.2% to $289.57 following strong quarterly results [4]

Financial Data and Key Metrics Changes - The company reported a total revenue increase of 22% to $64 billion, driven by strong demand in pharmaceuticals and growth across all five operating segments [10][11] - Operating earnings grew by 37% and EPS increased by 36%, with Q1 EPS reported at $2.55 [9][11] - Gross profit rose by 22% to $2.3 billion, while SG&A expenses increased by 14% to $1.5 billion [10][11] - The effective tax rate for Q1 was 21.9%, about 100 basis points better than the previous year [11] Business Line Data and Key Metrics Changes - Pharmaceutical and Specialty Solutions segment revenue increased by 23% to $59 billion, with segment profit rising by 26% to $667 million [12] - The GMPD segment saw a revenue increase of 2% to $3.2 billion, with profit rising to $46 million [13][14] - Other businesses reported a revenue increase of 38% to $1.6 billion and a profit increase of 60% to $166 million [15] Market Data and Key Metrics Changes - The company experienced strong pharmaceutical demand across brand, specialty, generics, and consumer health, with approximately 6 percentage points of revenue growth attributed to GLP-1 sales [12] - The GMPD segment faced slight headwinds from tariffs, with expectations of increased tariff costs in the second quarter [14][20] Company Strategy and Development Direction - The company is focused on expanding its Specialty Alliance and integrating the Solaris Health acquisition to enhance its multi-specialty platform [6][24] - Investments are being made in modernizing the pharmaceutical distribution network and expanding capabilities in Biopharma Solutions and MSO platforms [23][28] - The company aims to leverage its unique breadth of capabilities to create value for providers, manufacturers, and patients [8][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand environment and the company's ability to execute its strategic priorities [5][8] - The company raised its full-year EPS guidance to a range of $9.65-$9.85, reflecting anticipated growth driven by acquisitions and strong performance [10][17] - Management highlighted the importance of ongoing investments in technology and infrastructure to support future growth [23][28] Other Important Information - The company generated $1.3 billion in adjusted free cash flow during Q1 and returned $500 million to shareholders through dividends and share repurchases [16] - The company is increasing its adjusted free cash flow guidance to a range of $3 billion-$3.5 billion for the full year [17] Q&A Session Summary Question: Broader momentum and M&A contribution - Management noted strong demand trends and highlighted that the Specialty business was a strong performer, contributing about 8% to Q1 growth, with Solaris expected to add 3% to that [33][39] Question: Policy changes and opportunities - Management indicated that while the impact of policy changes is hard to define, they align with the administration's intent to improve access to affordable healthcare, which could drive utilization positively [44][47] Question: Growth outlook for Pharmaceutical and Specialty Solutions - Management emphasized that they are focused on what they can control, expecting strong demand and continued growth in specialty and generics, with M&A contributing significantly to growth [51][56] Question: Competitive landscape changes - Management acknowledged that recent competitor divestitures could create opportunities, but emphasized their focus on service levels and performance to remain the supplier of choice [90][91] Question: MSO assets and drug spending trends - Management highlighted diverse revenue streams within MSOs, with strong growth in autoimmune, neurology, and oncology, and noted that drug spending is a significant but not exclusive part of MSO revenue [94][95]

Financial Data and Key Metrics Changes - The company reported a total revenue increase of 22% to $64 billion, driven by strong demand in pharmaceuticals and growth across all five operating segments [10][11] - Operating earnings grew by 37% and EPS increased by 36%, with Q1 EPS reported at $2.55 [9][10] - Gross profit rose by 22% to $2.3 billion, while SG&A expenses increased by 14% to $1.5 billion [10][11] - The effective tax rate for Q1 was 21.9%, about 100 basis points better than the previous year [11] Business Line Data and Key Metrics Changes - Pharmaceutical and Specialty Solutions segment revenue increased by 23% to $59 billion, with segment profit rising by 26% to $667 million [12] - The GMPD segment saw a revenue increase of 2% to $3.2 billion, with profit rising to $46 million [13][14] - Other businesses reported a revenue increase of 38% to $1.6 billion and a profit increase of 60% to $166 million [15] Market Data and Key Metrics Changes - The company experienced strong pharmaceutical demand across brand, specialty, generics, and consumer health, with approximately 6 percentage points of revenue growth attributed to GLP-1 sales [12] - The GMPD segment faced slight headwinds from tariffs, which are expected to increase in Q2 [14][20] Company Strategy and Development Direction - The company is focused on expanding its Specialty Alliance and integrating Solaris Health to enhance its multi-specialty platform [6][24] - Investments are being made to modernize the national pharmaceutical distribution network and improve service levels [23] - The company is committed to innovation and expanding its service offerings, particularly in home health care and biopharma solutions [28][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand environment and the company's ability to capitalize on it, with an increased EPS guidance range of $9.65 to $9.85 for the fiscal year [10][17] - The company anticipates continued strong demand in pharmaceuticals and specialty solutions, with a focus on operational execution and efficiency [23][30] Other Important Information - The company generated $1.3 billion in adjusted free cash flow during Q1 and returned $500 million to shareholders through dividends and share repurchases [16] - The company is increasing its adjusted free cash flow guidance to a range of $3 billion to $3.5 billion for the full year [17] Q&A Session Summary Question: Broader momentum and M&A contribution - Management highlighted strong demand trends and the contribution of MSO platforms to growth, with Solaris Health expected to add approximately 3% to the overall growth [33][40] Question: Policy changes and opportunities - Management noted that policy changes aimed at improving access to affordable healthcare could be neutral to positive for the company, driving utilization [46][48] Question: Growth outlook for Pharmaceutical and Specialty Solutions - Management indicated that while strong growth is expected, it will not be outsized compared to historical levels, with a focus on operational improvements [52][54] Question: Competitive landscape changes - Management acknowledged that a competitor's divestiture could create opportunities, but emphasized the importance of service level and performance [90][91] Question: MSO assets and drug spending trends - Management confirmed that specialty growth is broad across therapeutic areas, with a focus on autoimmune, neurology, and oncology [95][96]

Financial Data and Key Metrics Changes - The company reported a total revenue increase of 22% to $64 billion, driven by strong demand across all five operating segments [11][12] - Operating earnings grew by 37% and EPS increased by 36%, with Q1 EPS reported at $2.55 [9][12] - Gross profit rose by 22% to $2.3 billion, while SG&A expenses increased by 14% to $1.5 billion [11][12] - The effective tax rate for Q1 was 21.9%, about 100 basis points better than the previous year [12] Business Line Data and Key Metrics Changes - **Pharmaceutical and Specialty Solutions**: Revenue increased by 23% to $59 billion, with segment profit up 26% to $667 million, driven by brand and specialty pharmaceutical sales [12][13] - **GMPD**: Revenue grew by 2% to $3.2 billion, with profit increasing by $38 million to $46 million, supported by volume growth from existing customers [14] - **Other Businesses**: Revenue surged by 38% to $1.6 billion, with segment profit rising by 60% to $166 million, reflecting strong demand across all three businesses [15][16] Market Data and Key Metrics Changes - The company experienced strong demand trends across its pharmaceutical segment, particularly in brand and specialty products, with approximately 6 percentage points of revenue growth attributed to GLP-1 sales [12][13] - The GMPD segment saw over 6% revenue growth in the U.S. [14] - The integration of ADS into At Home Solutions is progressing well, with earlier realization of planned synergies [15][16] Company Strategy and Development Direction - The company is focused on expanding its Specialty Alliance platform and enhancing its capabilities through the acquisition of Solaris Health, which is expected to close shortly [6][11] - Investments are being made to modernize the national pharmaceutical distribution network and improve operational efficiency [25][26] - The company aims to leverage its MSO platforms to broaden its impact in key therapeutic areas such as autoimmune, urology, and oncology [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's momentum and raised full-year EPS guidance to a range of $9.65 to $9.85, reflecting 17% to 20% growth from the prior year [11][18] - The company anticipates continued strong demand in the pharmaceutical sector and expects to benefit from the integration of recent acquisitions [18][19] - Management highlighted the importance of maintaining service levels and operational performance to capitalize on market opportunities [58][100] Other Important Information - The company generated $1.3 billion in adjusted free cash flow during Q1 and ended the quarter with a cash position of $4.6 billion [17] - The company is increasing its adjusted free cash flow guidance to a new range of $3 billion to $3.5 billion for the full year [18] Q&A Session Summary Question: What is the broader momentum going forward and what has driven the upside in Q1? - Management noted strong demand across the board and highlighted that the Specialty business was trending above historical levels, contributing significantly to growth [36][43] Question: Does the guidance include Rite Aid from CVS? - Management indicated that while they do not support Rite Aid, they are likely picking up a greater share of that volume due to strong performance across various customers [49][51] Question: How do you view the growth outlook for the Pharmaceutical and Specialty Solutions segment? - Management emphasized that they are focused on what they can control, expecting strong utilization and continued demand, while also factoring in contributions from acquisitions [56][58] Question: What is the impact of recent policy changes in D.C.? - Management stated that they align with the administration's intent to ensure access to affordable healthcare, which could drive utilization positively [52][53] Question: Can you discuss the onboarding of distribution businesses from recent acquisitions? - Management confirmed that the onboarding of distribution for ION and GIA is going well and is included in the guidance, while Solaris Health's distribution will be addressed once the acquisition closes [94][96] Question: What opportunities arise from competitors divesting their businesses? - Management noted that they continue to focus on service levels and performance, which positions them favorably in the competitive landscape [99][100]

Core Insights - Cardinal Health reported quarterly earnings of $2.55 per share, exceeding the Zacks Consensus Estimate of $2.21 per share, and showing an increase from $1.88 per share a year ago, resulting in an earnings surprise of +15.38% [1] - The company achieved revenues of $64.01 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.39%, compared to $52.28 billion in the same quarter last year [2] - Cardinal shares have increased by approximately 39.1% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.23, with expected revenues of $62.1 billion, and for the current fiscal year, the EPS estimate is $9.45 on revenues of $249 billion [7] - The estimate revisions trend for Cardinal was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Dental Supplies industry, to which Cardinal belongs, is currently ranked in the top 21% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - McKesson, another company in the same industry, is expected to report quarterly earnings of $8.92 per share, reflecting a year-over-year change of +26.2%, with revenues anticipated to be $104.66 billion, up 11.8% from the previous year [9][10]

Revenue and Earnings Growth - Revenue for the three months ended September 30, 2025, increased 22 percent to $64.0 billion from the prior-year quarter due to branded and specialty pharmaceutical sales growth[13] - GAAP operating earnings for the same period increased 18 percent to $668 million, primarily due to the acquisition of management services organization platforms and increased contribution from branded and specialty pharmaceutical products[15] - Non-GAAP operating earnings for the three months ended September 30, 2025, increased 37 percent to $857 million, driven by the impact of acquisitions and growth from existing customers within the GMPD segment[16] - GAAP diluted EPS increased 11 percent to $1.88, while non-GAAP diluted EPS increased 36 percent to $2.55 from the prior-year quarter[18] - Pharmaceutical and Specialty Solutions segment revenue increased 23 percent to $59.2 billion, primarily due to sales growth from existing and new customers[33] - The company reported a 12% increase in non-GAAP earnings for the same quarter last year, totaling $625 million[88] - Net earnings attributable to Cardinal Health, Inc. for Q1 Fiscal 2026 were $450 million, compared to $416 million in Q1 Fiscal 2025, representing an 8.2% increase[106] Acquisitions and Investments - The company announced the acquisition of Solaris Health for approximately $1.9 billion, which is expected to enhance its MSO capabilities[20] - The company announced the acquisition of Solaris Health for approximately $1.9 billion in cash, with additional common units issued to physicians and management valued at around $500 million[70] - The acquisition of Advanced Diabetes Supply Group was completed for approximately $1.0 billion in cash[131] - The company completed the acquisition of GI Alliance for approximately $2.8 billion in cash, with a 73% ownership interest acquired[132] - Total identifiable net assets acquired from Urology America, ADS, GIA, and ION were valued at $381 million, $1.049 billion, $2.785 billion, and $1.069 billion respectively[136] - The company plans to finance the Solaris Health acquisition with cash proceeds from recent debt financing and cash on hand[130] Financial Performance and Margins - Gross margin increased 22 percent to $2.3 billion, primarily due to the acquisition of MSO platforms and increased contributions from branded pharmaceutical products[38] - Total segment profit rose by 37% to $879 million, with Pharmaceutical and Specialty Solutions profit increasing by 26% to $667 million[42][43] - Global Medical Products and Distribution segment profit increased to $46 million, driven by growth from existing customers[44] - Other segment profit surged by 60% to $166 million, attributed to the performance of at-Home Solutions and the acquisition of ADS[45] - Cash flows from operating activities provided $973 million, a significant recovery from a cash outflow of $1,647 million in the prior year[113] Expenses and Liabilities - SG&A expenses increased by 14% to $1.5 billion from the prior-year quarter, primarily due to the acquisition of MSO platforms and ADS[40] - Interest expense increased to $80 million from $32 million in the prior-year quarter, primarily due to additional debt financing for recent acquisitions[53] - Total current liabilities increased to $40,268 million as of September 30, 2025, compared to $38,897 million at June 30, 2025[110] - Long-term obligations increased to $9.0 billion as of September 30, 2025, up from $8.5 billion at June 30, 2025[154] Tax and Legal Matters - The effective tax rate for the three months ended September 30, 2025, was 24.1%, compared to 23.0% in the prior year[54] - The company had $894 million of unrecognized tax benefits as of September 30, 2025, which could impact the effective tax rate if recognized[192] - The company is cooperating with a Department of Justice investigation regarding potential violations of the Anti-Kickback Statute and False Claims Act[184] Cash and Liquidity - Cash and equivalents balance was $4.6 billion at September 30, 2025, up from $3.9 billion at June 30, 2025[56] - The company deployed $500 million for debt repayment and $375 million for share repurchases during the three months ended September 30, 2025[57][69] - Cash and equivalents rose to $4,593 million as of September 30, 2025, compared to $3,874 million at June 30, 2025, reflecting improved liquidity[110] Share Repurchase and Dividends - The company has $2.4 billion remaining under its $3.5 billion share repurchase program approved on June 7, 2023, which is set to expire on December 31, 2027[103] - The company declared cash dividends of $0.5107 per common share, slightly up from $0.5056 per share in the previous year[106] Risk Factors - The company faces risks related to tariffs that may impact costs and supply chain dynamics, potentially affecting financial results[27] - The company accrued $4.3 billion for opioid-related matters as of September 30, 2025, with payments totaling $403 million and $798 million made during the three months and fiscal year 2025, respectively[173] Derivative Instruments and Hedging - The company utilizes derivative financial instruments primarily to manage interest rate risk and currency exchange risk, without engaging in trading or speculative purposes[197] - During the three months ended September 30, 2025, the company entered into pay-floating interest rate swaps with total notional amounts of $300 million, designated as fair value hedges[203] - In September 2025, the company entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2027 to hedge foreign currency risk associated with net investment positions[206]

Q1 FY26 Financial Performance - Revenue increased by 22% to $64,009 million[9] - Gross Margin increased by 22% to $2,319 million[9] - Operating Earnings increased by 18% to $668 million on a GAAP basis, and 37% to $857 million on a non-GAAP basis[9] - Net Earnings attributable to Cardinal Health, Inc increased by 8% to $450 million on a GAAP basis, and 33% to $611 million on a non-GAAP basis[9] - Diluted EPS attributable to Cardinal Health, Inc increased by 11% to $1.88 on a GAAP basis, and 36% to $2.55 on a non-GAAP basis[9] Segment Performance - Pharmaceutical and Specialty Solutions revenue increased by 23% to $59,205 million, with segment profit increasing by 26% to $667 million[11] - Global Medical Products and Distribution revenue increased by 2% to $3,184 million, with segment profit increasing significantly to $46 million[16] - Other (NPHS, at-Home Solutions, and OptiFreight) revenue increased by 38% to $1,641 million, with segment profit increasing by 60% to $166 million[21] FY26 Outlook - Non-GAAP EPS outlook revised upwards to $9.65 - $9.85 from the previous $9.30 to $9.50[29] - Non-GAAP adjusted free cash flow is expected to be $3.0 billion - $3.5 billion, revised upwards from the previous $2.75 billion - $3.25 billion[29] - The company anticipates ~$325 million in Interest and Other expenses[29]

Core Insights - Cardinal Health raised its annual adjusted profit forecast after exceeding first-quarter profit estimates, driven by strong demand for specialty medicines and branded drugs [1] Financial Performance - The company reported a strong first-quarter profit, which surpassed market expectations [1] - The increase in profit forecast indicates positive growth prospects for the company in the upcoming fiscal year [1] Market Demand - There is a notable increase in demand for costly specialty medicines, which has significantly contributed to the company's financial performance [1] - The performance in branded drugs also played a crucial role in the overall profit increase [1]

Financial Performance - Cardinal Health reported Q1 FY26 revenues of $64 billion, a 22% increase from $52.3 billion in Q1 FY25[2] - GAAP operating earnings rose 18% to $668 million, while GAAP diluted EPS increased 11% to $1.88[3] - Non-GAAP operating earnings increased 37% to $857 million, with non-GAAP diluted EPS rising 36% to $2.55[3] - Net earnings for the first quarter of 2026 were $454 million, compared to $417 million in the first quarter of 2025, reflecting a growth of 9%[26] - Revenue from Global Medical Products and Pharmaceutical and Specialty Solutions Distribution reached $59,205 million in the first quarter of 2026, a 23% increase from $47,990 million in the same period of 2025[28] - Segment profit for Global Medical Products and Pharmaceutical and Specialty Solutions Distribution rose to $667 million, a 26% increase from $530 million year-over-year[28] Guidance and Future Outlook - The company raised its fiscal year 2026 non-GAAP EPS guidance to a range of $9.65 to $9.85, reflecting a 17% to 20% growth[10] - Cardinal Health anticipates completing the acquisition of Solaris Health in early November 2025[3] Segment Performance - Revenue for the Pharmaceutical and Specialty Solutions segment increased 23% to $59.2 billion, with segment profit up 26% to $667 million[4] - The Global Medical Products and Distribution segment saw a 2% revenue increase to $3.2 billion, with segment profit rising to $46 million[6] - Other segment revenue grew 38% to $1.6 billion, with segment profit increasing 60% to $166 million[8] Cash Flow and Liquidity - Net cash provided by operating activities was $973 million in the first quarter of 2026, a significant recovery from a cash outflow of $1,647 million in the first quarter of 2025[34] - Non-GAAP adjusted free cash flow for the first quarter of 2026 was $1,269 million, compared to a negative $1,361 million in the first quarter of 2025[34] - Cash and equivalents at the end of the period increased to $4,593 million, up from $2,867 million at the end of the first quarter of 2025[26] Assets and Liabilities - Total assets increased to $55,228 million as of September 30, 2025, up from $53,122 million on June 30, 2025, representing a growth of 4%[24] - Accounts payable increased to $36,860 million as of September 30, 2025, up from $34,713 million on June 30, 2025, indicating a growth of 6%[24] - Total current liabilities rose to $40,268 million as of September 30, 2025, compared to $38,897 million on June 30, 2025, marking an increase of 4%[24] Shareholder Actions - The company initiated a $375 million accelerated share repurchase program in Q1 FY26[14] - Cardinal Health announced the opening of a new flagship Pharmaceutical and Specialty Solutions distribution center in Indianapolis, expected to be operational by Fall 2027[14] Non-GAAP Metrics and Adjustments - Non-GAAP adjusted free cash flow is provided as a supplemental metric to assess cash flow available for working capital needs, debt repayments, and strategic acquisitions[40] - Non-GAAP operating earnings exclude various costs such as LIFO charges, state opioid assessments, restructuring costs, and acquisition-related expenses[45] - Non-GAAP net earnings attributable to Cardinal Health, Inc. exclude significant non-recurring items, enhancing the clarity of ongoing business performance[48] - Non-GAAP gross margin excludes LIFO charges, providing a clearer view of operational efficiency[44] - Non-GAAP effective tax rate adjusts for various excluded items, offering a more accurate reflection of tax obligations[49] - The company emphasizes the importance of adjusted free cash flow as a measure for assessing financial health and strategic flexibility[51] Accounting and Reporting - The company did not recognize any LIFO charges or credits during the periods presented, facilitating comparison of current financial results to historical results[39] - The occurrence and timing of excluded items could significantly impact the company's fiscal 2026 GAAP results[42] - Over the past five fiscal years, excluded items have impacted the company's EPS from $1.79 to $8.44, including a $6.79 charge related to goodwill impairment in fiscal 2022[42] - The company does not provide GAAP outlook due to the unpredictability of excluded items, which are not part of routine operating activities[41]

Core Insights - Cardinal Health reported a strong first quarter for fiscal year 2026, with revenues of $64 billion, marking a 22% increase from the previous year [1][2] - The company raised its fiscal 2026 outlook based on this performance, anticipating non-GAAP diluted EPS in the range of $9.65 to $9.85, reflecting a growth of 17% to 20% [10][11] Financial Performance - First quarter fiscal year 2026 revenues reached $64 billion, up from $52.3 billion in the same quarter of fiscal year 2025, representing a 22% year-over-year increase [2][11] - GAAP operating earnings increased by 18% to $668 million, while non-GAAP operating earnings rose by 37% to $857 million [1][11] - GAAP diluted EPS increased by 11% to $1.88, and non-GAAP diluted EPS surged by 36% to $2.55 [1][11] Segment Performance - The Pharmaceutical and Specialty Solutions segment generated revenues of $59.2 billion, a 23% increase from $48 billion in the prior year, with segment profit rising 26% to $667 million [3][4] - The Global Medical Products and Distribution segment saw a modest revenue increase of 2% to $3.2 billion, with segment profit significantly improving from $8 million to $46 million [5][7] - The "Other" segment reported a 38% revenue increase to $1.6 billion, with segment profit growing 60% to $166 million, driven by various operating segments [8][9] Guidance and Outlook - Cardinal Health raised its guidance for non-GAAP diluted EPS to a range of $9.65 to $9.85, up from the previous range of $9.30 to $9.50, reflecting strong first quarter performance and expected contributions from the acquisition of Solaris Health [10][11] - The company also increased its adjusted free cash flow expectations to $3.0 billion to $3.5 billion, up from $2.75 billion to $3.25 billion [10][11] Recent Developments - Cardinal Health's Sonexus Access and Patient Support business onboarded over 30 new specialty therapies in Q1, supporting growth expectations of over 30% for the BioPharma Solutions business in fiscal year 2026 [19] - The company announced the opening of a new flagship Pharmaceutical and Specialty Solutions distribution center in Indianapolis, expected to be operational by Fall 2027 [19] - An accelerated share repurchase program of $375 million was initiated in the first quarter of fiscal year 2026 [19]